Number of the records: 1  

lenalidomid

  1. SYSd000077269
    LBL
      
    00000nz--a2200181n--4500
    005
      
    20250606222642.0
    008
      
    190101|||anznnbabn-----------|-a|a------
    040
      
    $b slo $a BA006 $d BA006
    065
      
    $a D02.241.223.805.810.400
    065
      
    $a D03.383.621.808.519
    065
      
    $a D03.633.100.513.750.563
    066
      
    $a 01 $c 03
    150
      
    $a lenalidomid $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo
    450
      
    $w v $a 2,6-piperidíndion, 3-(4-amino-1,3-dihydro-1-oxo-2H- izoindol-2-yl)- $2 slo
    450
      
    $w v $a 3-(4-amino-1-oxoizoindolín-2-yl)piperidíne-2,6-dion $2 slo
    450
      
    $w v $a Revimid $2 slo
    450
      
    $w v $a Revlimid $2 slo
    550
      
    $7 sllk_us_auth*d007155 $Y Immunologic Factors $w P $a faktory imunologické
    550
      
    $7 sllk_us_auth*d020533 $Y Angiogenesis Inhibitors $w P $a inhibítory angiogenézy
    665
      
    $a 2019 (2002) $2 eng
    680
    9-
    $i A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. $2 eng
    750
    -2
    $a Lenalidomide $2 eng
    980
      
    $x M
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.